PL355818A1 - Nowe połączenie nieuspokajających środków antyhistaminowych z substancjami, mającymi wpływ na działanie leukotrienów, do leczenia nieżytu nosa/zapalenia spojówek - Google Patents

Nowe połączenie nieuspokajających środków antyhistaminowych z substancjami, mającymi wpływ na działanie leukotrienów, do leczenia nieżytu nosa/zapalenia spojówek

Info

Publication number
PL355818A1
PL355818A1 PL01355818A PL35581801A PL355818A1 PL 355818 A1 PL355818 A1 PL 355818A1 PL 01355818 A PL01355818 A PL 01355818A PL 35581801 A PL35581801 A PL 35581801A PL 355818 A1 PL355818 A1 PL 355818A1
Authority
PL
Poland
Prior art keywords
histamines
leukotriene
conjunctivitis
influence
action
Prior art date
Application number
PL01355818A
Other languages
English (en)
Other versions
PL198357B1 (pl
Inventor
Hildegard Kuss
Jurgen Engel
Istvan Szelenyi
Original Assignee
Viatris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh & Co Kg filed Critical Viatris Gmbh & Co Kg
Publication of PL355818A1 publication Critical patent/PL355818A1/pl
Publication of PL198357B1 publication Critical patent/PL198357B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL355818A 2000-02-17 2001-02-05 Preparat farmaceutyczny do leczenia alergicznego i/lub naczynioruchowego nieżytu nosa lub alergicznego zapalenia spojówek, lek na bazie tego preparatu oraz sposób otrzymywania leku PL198357B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10007203A DE10007203A1 (de) 2000-02-17 2000-02-17 Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
PCT/EP2001/001190 WO2001060407A2 (de) 2000-02-17 2001-02-05 Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis

Publications (2)

Publication Number Publication Date
PL355818A1 true PL355818A1 (pl) 2004-05-17
PL198357B1 PL198357B1 (pl) 2008-06-30

Family

ID=7631276

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355818A PL198357B1 (pl) 2000-02-17 2001-02-05 Preparat farmaceutyczny do leczenia alergicznego i/lub naczynioruchowego nieżytu nosa lub alergicznego zapalenia spojówek, lek na bazie tego preparatu oraz sposób otrzymywania leku

Country Status (26)

Country Link
US (1) US6436924B2 (pl)
EP (1) EP1265615B1 (pl)
JP (1) JP5529362B2 (pl)
KR (1) KR100764329B1 (pl)
CN (1) CN1241569C (pl)
AR (1) AR027528A1 (pl)
AT (1) ATE287266T1 (pl)
AU (1) AU781177B2 (pl)
BR (1) BR0108445A (pl)
CZ (1) CZ296395B6 (pl)
DE (2) DE10007203A1 (pl)
DK (1) DK1265615T3 (pl)
ES (1) ES2236189T3 (pl)
HU (1) HU228927B1 (pl)
IL (2) IL151106A0 (pl)
MX (1) MXPA02008064A (pl)
NO (1) NO328153B1 (pl)
NZ (1) NZ520470A (pl)
PL (1) PL198357B1 (pl)
PT (1) PT1265615E (pl)
RU (1) RU2292208C2 (pl)
SK (1) SK285990B6 (pl)
TW (1) TWI296525B (pl)
UA (1) UA72587C2 (pl)
WO (1) WO2001060407A2 (pl)
ZA (1) ZA200206575B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP2006508180A (ja) * 2002-10-17 2006-03-09 デコード ジェネティクス イーエッチエフ． 心筋梗塞に対する感受性遺伝子；治療の方法
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
EP1670445A2 (en) * 2003-09-17 2006-06-21 Decode Genetics EHF. Methods of preventing or treating recurrence of myocardial infarction
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
HRP20120286T1 (hr) * 2004-02-06 2012-04-30 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP1827499A4 (en) 2004-11-24 2010-03-17 Medpointe Healthcare Inc COMPOSITIONS COMPRISING AZELASTIN AND METHODS OF USE
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
US20100068301A1 (en) 2006-11-30 2010-03-18 Hutchinson John H Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2009067317A2 (en) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Use of levocabastine for modulating generation of pro- inflammatory cytokines
PT3943069T (pt) 2009-03-17 2025-02-21 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
CN104042617A (zh) 2009-04-29 2014-09-17 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
KR101943490B1 (ko) 2013-03-13 2019-04-17 플랫틀리 디스커버리 랩, 엘엘씨 피리다지논 화합물 및 낭성 섬유증을 치료하는 방법
KR101555908B1 (ko) * 2013-12-19 2015-09-25 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
CA2938879C (en) 2014-02-04 2023-05-09 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2020146822A1 (en) * 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
WO2020173534A1 (en) 2019-02-28 2020-09-03 Coloplast A/S A sensor patch for attachment to a base plate
CN110721189A (zh) * 2019-11-19 2020-01-24 贵州云峰药业有限公司 一种皮肤消毒剂
NZ790643A (en) 2020-02-03 2023-05-26 Taro Pharma Ind Topical montelukast formulations
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
CN116284470B (zh) * 2023-02-15 2024-08-02 广西中医药大学 一种海蛇尾多糖硫酸酯衍生物的制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE68904475T2 (de) 1988-04-27 1993-05-13 Schering Corp Gewisse paf-antagonist/antihistamin-mischungen und verfahren.
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
EP1214937B1 (en) * 1992-08-03 2007-05-30 Sepracor Inc. Terfenadine carboxylate and the treatment of dermal irritation
CZ248798A3 (cs) * 1996-02-08 1999-01-13 Merck And Co., Inc. Farmaceutický prostředek
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
US6242179B1 (en) 1997-12-17 2001-06-05 Incyte Pharmaceuticals, Inc. Human phosphatases
JP2001526232A (ja) * 1997-12-23 2001-12-18 シェーリング コーポレイション 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
AR027528A1 (es) 2003-04-02
CN1241569C (zh) 2006-02-15
MXPA02008064A (es) 2004-04-05
PT1265615E (pt) 2005-05-31
CZ296395B6 (cs) 2006-03-15
HUP0204079A3 (en) 2006-07-28
DE10007203A1 (de) 2001-08-23
NO20023818L (no) 2002-08-12
KR100764329B1 (ko) 2007-10-05
NO328153B1 (no) 2009-12-21
BR0108445A (pt) 2003-04-01
CZ20022700A3 (cs) 2002-11-13
EP1265615A2 (de) 2002-12-18
SK285990B6 (sk) 2008-01-07
TWI296525B (en) 2008-05-11
KR20020083161A (ko) 2002-11-01
NO20023818D0 (no) 2002-08-12
IL151106A0 (en) 2003-04-10
ATE287266T1 (de) 2005-02-15
DE50105126D1 (de) 2005-02-24
UA72587C2 (uk) 2005-03-15
RU2002123345A (ru) 2004-03-20
IL151106A (en) 2008-06-05
AU4058401A (en) 2001-08-27
EP1265615B1 (de) 2005-01-19
JP5529362B2 (ja) 2014-06-25
SK11752002A3 (sk) 2002-11-06
ES2236189T3 (es) 2005-07-16
HK1053792A1 (en) 2003-11-07
HU228927B1 (en) 2013-06-28
HUP0204079A2 (hu) 2003-04-28
WO2001060407A3 (de) 2002-03-07
WO2001060407A2 (de) 2001-08-23
PL198357B1 (pl) 2008-06-30
DK1265615T3 (da) 2005-05-30
CN1400903A (zh) 2003-03-05
JP2003522803A (ja) 2003-07-29
ZA200206575B (en) 2003-05-14
RU2292208C2 (ru) 2007-01-27
US20010025040A1 (en) 2001-09-27
AU781177B2 (en) 2005-05-12
NZ520470A (en) 2004-05-28
US6436924B2 (en) 2002-08-20

Similar Documents

Publication Publication Date Title
IL151106A0 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
IL164533A0 (en) Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
AP2006003558A0 (en) Polymorphic forms of 3-(4-amino-1oxo-1,3 dilhydro-isoindol-2-yl)-piperidine-2,6-dione.
ZA200401015B (en) Compounds effecting glucokinase.
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
ZA200204830B (en) Novel method for down-regulation of amyloid.
EP1384493A4 (en) IRRADIATOR
MXPA03001007A (es) Procedimientos para la preparacion de absorbentes de uv de benzotriazol.
GB0512558D0 (en) Microorganisms for well treatment
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
ZA200209047B (en) Process for permanently reshaping the hair using particular aminosilicones.
GB0122729D0 (en) Improved waste treatment
EP1465968A4 (en) METHODS OF TREATING DISTILLATE DEODORIZER
MXPA03005673A (es) Inhibidores de 8-arilquinolin-fosfodiesterasa-4-substituidos.
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
EG24462A (en) Compounds for treating fundic disaccomodation
AU2003222022A8 (en) Methods for treating deodorizer distillate
HU0002837D0 (en) Strain-setting device for tendonrekonstruction or replacement
SI1265615T1 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
MXPA03004195A (es) Terapia combinada para los trastornos dependientes de estrogenos.
MXPA02000714A (es) Aparato para triturar material.
IL188685A0 (en) Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
ITPD20000203A0 (it) Dispositivi di sicurezza per portoni sezionali.
TW479626U (en) Treatment device for junk
MXPA03003068A (es) Proceso para preparacion de tiofenoles.